Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of icaritin in preparation of medicine for treating triple negative breast cancer

A triple-negative breast cancer, icariin technology, applied in drug combinations, sexual diseases, pharmaceutical formulations, etc., can solve the problems of mild biological effects, large side effects, restricting the modernization process of traditional Chinese medicine, etc., to inhibit the occurrence of EMT, inhibit the The effect of cell proliferation, good therapeutic effect

Pending Publication Date: 2022-07-29
LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Patients with triple-negative breast cancer are currently mainly treated with surgery and chemotherapy, but the treatment effect is not satisfactory and the side effects are large. Distressed by conditions that seriously affect quality of life, such as cardiovascular and neurological reactions
But on the other hand, we also see that compared with Western medicine, most Chinese medicines contain more than thousands of compounds, with various and complex components and structures, and mild biological effects. main obstacle

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of icaritin in preparation of medicine for treating triple negative breast cancer
  • Application of icaritin in preparation of medicine for treating triple negative breast cancer
  • Application of icaritin in preparation of medicine for treating triple negative breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1: Network Pharmacology Screening Analysis

[0040] 1.1 Collection of main active components and potential targets of Epimedium and Psoralea

[0041] In the embodiment of the present invention, Epimedium and Psoralea

[0042] The active ingredients of Epimedium and Psoralea were retrieved through the TCMSP database (https: / / tcmspw.com / tcmsp.php). Taking oral bioavailability (OB) ≥ 30% and drug-likeness (DL) ≥ 0.18 as screening conditions, drug-related active ingredients were collected. Find the corresponding target protein according to the active ingredient, and use the UniProt database (http: / / www.uniprot.org / ) to uniformly convert the name of the target protein into the target name.

[0043] The Gene Cards database (https: / / www.genecards.org) was searched with "breast cancer" as the search term to collect breast cancer-related targets. In order to clarify the interaction between disease-related targets and potential targets of traditional Chinese medicine, ...

Embodiment 2

[0052] Example 2: AHI in vitro cell experiment

[0053] 2.1 Detection of cell proliferation ability

[0054] Breast cancer cell lines MDA-MB-231 and 4T1 were purchased from the Cell Bank of the Chinese Academy of Sciences. AHI was purchased from Shanghai Weiao Medical Technology Co., Ltd. Cells in each group were seeded into 96-well plates. After 24 h, the medium was changed to fresh medium containing different concentrations of AHI (0, 5, 10, 20, 40, 80 and 160 μM). After 24 / 48h of drug intervention, cell viability was detected by MTT assay.

[0055] Through MTT experiments, it was found that AHI has inhibitory effects on different types of breast cancer cells MDA-MB-231, 4T1, MCF7, and SK-BR-3, among which the ability to inhibit the proliferation of MDA-MB-231, 4T1 triple-negative breast cancer cells strongest ( figure 2 B-2C). AHI interferes with IC of MDA-MB-231 cells 50 The values ​​were 278.68μM and 94.00μM at 24h and 48h, respectively. The IC of 4T1 cells 50 Th...

Embodiment 3

[0061] Example 3: AHI transcriptome sequencing

[0062] To further explore the mechanism of AHI in breast cancer, the control group and AHI (40 μM) treated 4T1 and MDA-MB-231 cells were subjected to transcriptome sequencing.

[0063] Trizol was used to extract 4T1 and MDA-MB-231 breast cancer cells and control cells treated with AHI (40 μM) in Example 2. Transcriptome sequencing was performed by Sangon (Shanghai, China) using the Illumina No-voseq platform. P<0.05 and Fold change≥1.5 were considered statistically significant.

[0064] In 4T1 cells, 59 genes were significantly up-regulated and 76 genes were significantly down-regulated in the AHI-treated group compared with the control group (fold change ≥ 1.5; P image 3 A, B). In MDA-MB-231 cells, compared with the control group, 144 genes were significantly up-regulated and 106 genes were significantly down-regulated in the AHI group ( image 3 D, E). AHI-treated 4T1 and MDA-MB-231 cells had different clustering genes th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of icaritin in preparation of a medicine for treating triple negative breast cancer. The herba epimedii-fructus psoraleae drug pair is researched for the first time through a network pharmacology research means, an effective component icaritin with a treatment effect on breast cancer is found, and further in-vivo and in-vitro experiments are carried out to verify that icaritin has the capability of inhibiting cell proliferation, invasion or migration, can up-regulate GPX1 expression and inhibit EMT generation, and can be used for treating breast cancer. Further, the anti-breast cancer effect is achieved.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine natural products, in particular to the application of icariin in the preparation of a medicine for treating triple-negative breast cancer. Background technique [0002] Breast cancer is a malignant tumor that seriously threatens women's health and is one of the most common causes of cancer deaths in women. According to the Global Cancer Statistics Report, the number of new cases of breast cancer in 2020 is as high as 2.3 million, ranking first among women in the world. In recent years, with the promotion of breast cancer molecular pathology and genotyping, triple-negative breast cancer has received more and more attention. Triple-negative breast cancer refers to breast cancer with negative expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 by immunohistochemical detection. Compared with other types of breast cancer, triple-ne...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P15/14A61P35/00A61P35/04
CPCA61K31/352A61P15/14A61P35/00A61P35/04
Inventor 史有阳刘胜周细秋韩向晖武媛媛李斐斐郑金洲杨剑锋
Owner LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com